Mackenzie Financial
WST icon

Mackenzie Financial’s West Pharmaceutical WST Stock Holding History

Mackenzie Financial’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.67M Buy
21,356
+64
+0.3% +$19.6K 0.01% 720
2026
Q1 		$5.34M Sell
21,292
-80,619
-79% -$20.1M 0.01% 651
2025
Q4 		$28.2M Buy
101,911
+9,241
+10% +$2.53M 0.03% 340
2025
Q3 		$24.3M Buy
92,670
+84,260
+1,002% +$20.5M 0.03% 350
2025
Q2 		$1.84M Sell
8,410
-83
-1% -$17.7K ﹤0.01% 826
2025
Q1 		$1.9M Buy
8,493
+929
+12% +$256K ﹤0.01% 802
2024
Q4 		$2.48M Buy
7,564
+634
+9% +$200K ﹤0.01% 718
2024
Q3 		$2.08M Sell
6,930
-399
-5% -$122K ﹤0.01% 716
2024
Q2 		$2.41M Sell
7,329
-318
-4% -$112K ﹤0.01% 690
2024
Q1 		$3.03M Buy
7,647
+270
+4% +$99.9K ﹤0.01% 651
2023
Q4 		$2.6M Sell
7,377
-7,932
-52% -$2.81M ﹤0.01% 678
2023
Q3 		$5.65M Buy
15,309
+8,043
+111% +$3.11M 0.01% 524
2023
Q2 		$2.75M Sell
7,266
-2,619
-26% -$936K ﹤0.01% 671
2023
Q1 		$3.42M Buy
9,885
+83
+0.8% +$24.3K 0.01% 625
2022
Q4 		$2.31M Sell
9,802
-890
-8% -$211K ﹤0.01% 650
2022
Q3 		$2.63M Buy
10,692
+464
+5% +$141K ﹤0.01% 637
2022
Q2 		$3.09M Buy
10,228
+265
+3% +$86.2K 0.01% 623
2022
Q1 		$4.09M Buy
9,963
+89
+0.9% +$34.8K 0.01% 616
2021
Q4 		$4.63M Sell
9,874
-5,838
-37% -$2.51M 0.01% 592
2021
Q3 		$6.67M Buy
15,712
+6,370
+68% +$2.69M 0.01% 521
2021
Q2 		$3.35M Buy
9,342
+1,260
+16% +$416K ﹤0.01% 633
2021
Q1 		$2.28M Buy
8,082
+1,128
+16% +$323K ﹤0.01% 667
2020
Q4 		$1.97M Sell
6,954
-4,170
-37% -$1.17M ﹤0.01% 610
2020
Q3 		$3.06M Buy
11,124
+1,638
+17% +$433K 0.01% 482
2020
Q2 		$2.15M Buy
9,486
+2,486
+36% +$488K 0.01% 546
2020
Q1 		$1.07M Buy
7,000
+5,594
+398% +$861K ﹤0.01% 627
2019
Q4 		$211K Buy
+1,406
New +$205K ﹤0.01% 1032
2019
Q1 		– Sell
-2,455
Closed -$241K – 1331
2018
Q4 		$241K Buy
2,455
+228
+10% +$24.7K ﹤0.01% 1070
2018
Q3 		$275K Buy
+2,227
New +$250K ﹤0.01% 1012

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Mackenzie Financial's WST Position: Q2 2026 in Review

Mackenzie Financial increased its West Pharmaceutical (WST) stake by 0.3% in Q2 2026, buying an estimated $19.6K and bringing the position to 21,356 shares worth $7.67M. The position accounts for 0.01% of the portfolio, ranked #720.

Mackenzie Financial first reported a position in WST in Q3 2018 and has held it in 29 quarters since. The position peaked at $28.2M in Q4 2025. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Mackenzie Financial held 21,356 shares of West Pharmaceutical worth $7.67M as of Q2 2026.
  • Mackenzie Financial bought 64 West Pharmaceutical shares in Q2 2026, an estimated $19.6K.
  • West Pharmaceutical made up 0.01% of Mackenzie Financial's portfolio in Q2 2026, its #720 holding.
  • Mackenzie Financial first reported a position in West Pharmaceutical in Q3 2018 and has held it in 29 quarters since.
  • Mackenzie Financial's West Pharmaceutical position peaked at $28.2M in Q4 2025.
  • 831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.